Real-World Treatment Study of Koselugo (Selumetinib)
AstraZeneca
200 participants
Jun 15, 2024
OBSERVATIONAL
Conditions
Summary
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, by physicians in routine clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea. This study will provide information on the Korean patient population that is treated with the study drug.
Eligibility
Inclusion Criteria2
- Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
- Provision of signed and dated written informed consent by the patient or legally acceptable representative
Exclusion Criteria2
- Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
- Provision of signed and dated written informed consent by the patient or legally acceptable representative
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06360406